Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
AVDL Analyst Ratings
Hold
0 Buy
10 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AVDL Stock 12 Month Forecast
Average Price Target
$20.29
▼(-4.92% Downside)
| Highest Price Target$22.50 | Average Price Target$20.29 | Lowest Price Target$18.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Jefferies
$20→$22.5
Hold
5.44%
Upside
Reiterated
11/26/25
Hold Rating on Avadel Pharmaceuticals Amid Acquisition Offer and Market UncertaintiesWe now think the chances of a competing bid are unlikely, after Lundbeck decided not to raise its Nov 14th offer of up to $23/sh (~$2.3B), which included a $2/sh CVR that was considered by AVDL as inferior, due to a lower probability of the CVR paying out. As such, we expect the ALKS/AVDL deal to close in Q1:26. Big picture: Lumryz is an approved once-nightly oxybate that is fundamentally different from JAZZ's twice-nightly oxybates Xyrem/Xywav in narcolepsy. Lumryz was previously guided to reach $265-275M in 2025, which seems conservative, as our Q4 sales estimate of $83M ($330M+ runrate) implies $280M+ of sales for the year. For Lumryz in IH ($500M-1B+ oppty), Phase III data is due early 2026, followed by a pot'l FDA approval as early as H1:27. Per AVDL/JAZZ's recent settlement, AVDL can sell Lumryz in IH after without any interference from JAZZ.
Wells Fargo
$20→$22.5
Hold
5.44%
Upside
Reiterated
11/20/25
H.C. Wainwright
$20
Hold
-6.28%
Downside
Reiterated
11/19/25
Craig-Hallum
―
Hold
―
Reiterated
11/19/25
Needham
―
Hold
―
Reiterated
11/05/25
UBS
$20
Hold
-6.28%
Downside
Downgraded
10/28/25
Leerink Partners
$22→$18.5
Hold
-13.31%
Downside
Downgraded
10/23/25
Deutsche Bank
$18→$20
Hold
-6.28%
Downside
Downgraded
10/23/25
Piper Sandler
$16→$18.5
Hold
-13.31%
Downside
Downgraded
10/22/25
LifeSci Capital
―
Hold
―
Downgraded
10/22/25
Avadel Pharmaceuticals (AVDL) was downgraded to a Hold Rating at LifeSci CapitalALKS announced an agreement to acquire AVDL for a total consideraon of $20/share in cash. The transacon is expected to close in 1Q26. This came right aer the news of a selement agreement between AVDL and JAZZ. Given the acquision announcement, we are moving to the sideline and downgrading our rang to Market Perform and removing our PT. Terms of acquision. The transacon is valued at $18.50/share in cash with a CVR for $1.50/share, conngent upon final FDA approval of LUMRYZ for Idiopathic Hypersomnia (IH) in adults by YE28 (together, this represents an equity value of about $2.1B). Downgrading to market perform and removing PT. Potenal upside situaons include emergence of addional potenal acquirers. Key risks include changes in regulatory environment, market downturns and potenal risks to compleon of acquision.
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Jefferies
$20→$22.5
Hold
5.44%
Upside
Reiterated
11/26/25
Hold Rating on Avadel Pharmaceuticals Amid Acquisition Offer and Market UncertaintiesWe now think the chances of a competing bid are unlikely, after Lundbeck decided not to raise its Nov 14th offer of up to $23/sh (~$2.3B), which included a $2/sh CVR that was considered by AVDL as inferior, due to a lower probability of the CVR paying out. As such, we expect the ALKS/AVDL deal to close in Q1:26. Big picture: Lumryz is an approved once-nightly oxybate that is fundamentally different from JAZZ's twice-nightly oxybates Xyrem/Xywav in narcolepsy. Lumryz was previously guided to reach $265-275M in 2025, which seems conservative, as our Q4 sales estimate of $83M ($330M+ runrate) implies $280M+ of sales for the year. For Lumryz in IH ($500M-1B+ oppty), Phase III data is due early 2026, followed by a pot'l FDA approval as early as H1:27. Per AVDL/JAZZ's recent settlement, AVDL can sell Lumryz in IH after without any interference from JAZZ.
Wells Fargo
$20→$22.5
Hold
5.44%
Upside
Reiterated
11/20/25
H.C. Wainwright
$20
Hold
-6.28%
Downside
Reiterated
11/19/25
Craig-Hallum
―
Hold
―
Reiterated
11/19/25
Needham
―
Hold
―
Reiterated
11/05/25
UBS
$20
Hold
-6.28%
Downside
Downgraded
10/28/25
Leerink Partners
$22→$18.5
Hold
-13.31%
Downside
Downgraded
10/23/25
Deutsche Bank
$18→$20
Hold
-6.28%
Downside
Downgraded
10/23/25
Piper Sandler
$16→$18.5
Hold
-13.31%
Downside
Downgraded
10/22/25
LifeSci Capital
―
Hold
―
Downgraded
10/22/25
Avadel Pharmaceuticals (AVDL) was downgraded to a Hold Rating at LifeSci CapitalALKS announced an agreement to acquire AVDL for a total consideraon of $20/share in cash. The transacon is expected to close in 1Q26. This came right aer the news of a selement agreement between AVDL and JAZZ. Given the acquision announcement, we are moving to the sideline and downgrading our rang to Market Perform and removing our PT. Terms of acquision. The transacon is valued at $18.50/share in cash with a CVR for $1.50/share, conngent upon final FDA approval of LUMRYZ for Idiopathic Hypersomnia (IH) in adults by YE28 (together, this represents an equity value of about $2.1B). Downgrading to market perform and removing PT. Potenal upside situaons include emergence of addional potenal acquirers. Key risks include changes in regulatory environment, market downturns and potenal risks to compleon of acquision.
Best Analysts Covering Avadel Pharmaceuticals
1 Month
xxx
Success Rate
2/2 ratings generated profit
Average Return
+0.85%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +0.85% per trade.
3 Months
xxx
Success Rate
2/2 ratings generated profit
Average Return
+13.60%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +13.60% per trade.
1 Year
Success Rate
2/2 ratings generated profit
Average Return
+13.60%
reiterated a buy rating 2 months ago
Copying Bryce Generon's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +13.60% per trade.
2 Years
xxx
Success Rate
2/2 ratings generated profit
Average Return
+13.60%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +13.60% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AVDL Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
4
3
4
4
3
Buy
3
8
14
15
8
Hold
9
7
8
13
17
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
18
26
32
28
Each month's total comprises the sum of three months' worth of ratings.
AVDL Financial Forecast
AVDL Stock Forecast FAQ
What is AVDL’s average 12-month price target, according to analysts?
Based on analyst ratings, Avadel Pharmaceuticals’s 12-month average price target is 20.29.
What is AVDL’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for AVDL, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AVDL a Buy, Sell or Hold?
Avadel Pharmaceuticals has a consensus rating of Hold which is based on 0 buy ratings, 10 hold ratings and 0 sell ratings.
What is Avadel Pharmaceuticals’s price target?
The average price target for Avadel Pharmaceuticals is 20.29. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $22.50 ,the lowest forecast is $18.50. The average price target represents -4.92% Decrease from the current price of $21.34.
The highest analyst price target is $22.50 ,the lowest forecast is $18.50. The average price target represents -4.92% Decrease from the current price of $21.34.
What do analysts say about Avadel Pharmaceuticals?
Avadel Pharmaceuticals’s analyst rating consensus is a Hold. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of AVDL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.